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ABSTRACT
Introduction: Clostridium difficile infection
(CDI) is the major cause of infectious nosoco-
mial diarrhoea and is associated with consider-
able morbidity, mortality and economic impact.
Bezlotoxumab administered in combination
with standard of care (SoC) antibiotic therapy
prevents recurrent CDI. This study assessed the
cost-effectiveness of bezlotoxumab added to
SoC, compared to SoC alone, to prevent the
recurrence of CDI in high-risk patients from the
Spanish National Health System perspective.
Methods: A Markov model was used to simulate
the natural history of CDI over a lifetime hori-
zon in five populations of patients at high risk
of CDI recurrence according to MODIFY trials:
(1) C 65 years old; (2) severe CDI; (3) immuno-
compromised; (4) C 1 CDI episode in the pre-
vious 6 months; and (5) C 65 years old and
with C 1 CDI episode in the previous 6 months.
The incremental cost-effectiveness ratio (ICER)
expressed as cost per quality-adjusted life-year
(QALY) gained was calculated. Deterministic
(DSA) and probabilistic sensitivity analyses
(PSA) were performed.
Results: In all patient populations (from 1 to
5), bezlotoxumab added to SoC reduced CDI
recurrence compared to SoC alone by 26.4, 19.5,
21.2, 26.6 and 39.7%, respectively. The
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resulting ICERs for the respective subgroups
were €12,724, €17,495, €9545, €7386, and
€4378. The model parameters with highest
impact on the ICER were recurrence rate (first),
mortality, and utility values. The probability
that bezlotoxumab was cost-effective at a will-
ingness-to-pay threshold of €21,000/QALY was
85.5%, 54.1%, 86.0%, 94.5%, 99.6%,
respectively.
Conclusion: The results suggest that bezlotox-
umab added to SoC compared to SoC alone is a
cost-effective treatment to prevent the recur-
rence of CDI in high-risk patients. The influence
of changes in model parameters on DSA results
was higher in patients C 65 years old, with
severe CDI and immunocompromised. Addi-
tionally, PSA estimated that the probability of
cost-effectiveness exceeded 85% in most
subgroups.
Funding: Merck Sharp & Dohme Corp.
Keywords: Bezlotoxumab; Clostridium difficile
infection; Cost-effectiveness
INTRODUCTION
Clostridium difficile infection (CDI) is the major
cause of infectious nosocomial diarrhoea and is
associated with considerable morbidity and
mortality, as well as a significant economic
impact on the healthcare systems of developed
countries [1]. The incidence of CDI increased by
70% in European countries from 4.1 to 7.0 cases
per 10,000 patient-bed days between 2008 and
2013, without taking into account the existence
of a considerable number of potentially missed
CDI diagnoses due to the frequent use of sub-
optimum laboratory diagnostic tests [2]. In
Spain, the estimated figure was 3.2 cases per
10,000 patient-bed days in 2013 [2], with half of
the episodes underdiagnosed [3].
The clinical burden of CDI ranges from
symptomless carriage, through mild or moder-
ate diarrhoea, to fulminant and sometimes fatal
pseudomembranous colitis [4]. One of the main
complications in treating CDI is the recurrence
of the infection [5] defined as CDI which re-
occurs within 8 weeks after the onset of a pre-
vious episode, provided the symptoms from the
previous episode resolved after completion of
initial treatment [6]. Most patients with an ini-
tial CDI episode respond to antibiotic treat-
ment; however, up to 25% of patients may
experience CDI recurrence within 30 days fol-
lowing treatment. Patients who experienced a
recurrent episode of CDI have a 45% probability
of a second recurrence, and this risk increases
with each subsequent recurrence [1, 7]. Several
risk factors have been identified for the devel-
opment of recurrent CDI; however, certain
subgroups of patients are more susceptible to
recurrence such as patients of an older age,
immunocompromised individuals those with a
history of CDI or patients with an initial clini-
cally severe CDI episode [8–16].
The economic burden of CDI is a result of
extended length of hospital stay (LoS), re-ad-
mission, laboratory tests and medication. In
Spain, the cost for treating C. difficile-associated
diarrhoea (CDAD) was estimated at €32.2 mil-
lion to the National Health System (NHS) in
2012 [17]. On average, the cost per episode was
€3901, €4875 and €5916, for initial infection,
first and second recurrence, respectively. The
main extra CDI-associated costs were due to the
extended LoS which was 7.4, 9.1 and 10.8 days
for initial infection, first and second recurrence,
respectively [17].
Bezlotoxumab is a new antitoxin agent (a
human monoclonal antibody against C. difficile
toxin B) which, administered during the course
of antibiotic therapy for CDI, is indicated for
the prevention of CDI recurrence in adults at
high risk of CDI recurrence [18].
The phase III MODIFY I and MODIFY II trials
[19] evaluated the efficacy and safety of a single
intravenous infusion of bezlotoxumab com-
pared to placebo in patients receiving standard
of care (SoC) oral antibiotic therapy for CDI
(metronidazole, vancomycin or fidaxomicin).
Results from pooled data analysis showed a
significantly lower rate of recurrent CDI with
bezlotoxumab than placebo in all participants
[16.5% (129 of 781) vs. 26.6% (206 of 773);
adjusted difference, - 10.0 percentage points;
95% confidence interval (CI), - 14.0 to - 6.0;
p value\ 0.0001]. Moreover, the absolute dif-
ference in CDI recurrence rate between bezlo-
toxumab and placebo was greater in
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subpopulations at high risk of CDI recurrence
than in the overall population.
Bezlotoxumab has been recently obtained
the marketing authorization in Spain [20].
Although many studies have assessed the cost-
effectiveness of antibiotic therapy for CDI [21],
only one published cost-effectiveness analysis
evaluating bezlotoxumab from a US payer per-
spective has been performed [22]. Due to the
increasing burden of CDI and the efficacy of
bezlotoxumab in reducing CDI recurrence, our
aim was to assess the cost-effectiveness of
bezlotoxumab in addition to SoC antibiotic
therapy as compared to SoC alone for the pre-
vention of recurrence in five subgroups of
patients at high risk of CDI recurrence within
the context of the Spanish NHS.
METHODS
Model Overview
A computer-based Markov health state transi-
tion model was developed in Microsoft Excel
based on MODIFY I/II trials [19]. The model was
previously adapted to the US setting [22] and for
the present study the model was adapted to the
Spanish context using local data.
The model evaluated the cost-effectiveness
of a single dose of bezlotoxumab 10 mg/kg
administered as an intravenous infusion com-
pared to placebo for the prevention of recur-
rence in five patient populations with CDI at
increased recurrence risk according to MODIFY
I/II trials [19]: (1) aged 65 years or older; (2)
clinically severe CDI (defined as a Zar score C 2;
scores range from 1 to 8, with higher scores
indicating more severe infection); (3) compro-
mised immunity (determination made on the
basis of medical history or use of immunosup-
pressive therapy for hematological malig-
nancy—including leukemia, lymphoma,
multiple myeloma—, an active malignancy
requiring recent cytotoxic chemotherapy,
receipt of a prior hematopoietic stem cell
transplant, receipt of a prior solid organ trans-
plant, asplenia, or neutropenia/pancytopenia
due to other conditions); (4) a history of CDI
(C 1 CDI episode in the previous 6 months); (5)
aged 65 years or older and a history of CDI (C 1
CDI episode in the previous 6 months). The
model structure is shown in Fig. 1. A cohort of
patients entered the model with mild/moderate
or a severe CDI episode. Patients with
mild/moderate CDI could experience a clinical
cure or a clinical failure. In addition, subjects
with severe CDI could undergo colectomy
Recurrent CDI
Clinical 
failure
Post-colectomy
Mild/ moderate 
CDI
Severe CDI
Mild/ moderate 
CDI
Clinical cure
Post-clinical 
failure
ColectomySevere CDI
All health states have transitions to death. 
Fig. 1 Markov model structure. All health states have transitions to death
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surgery. Clinical cure and clinical failure were
defined as per the MODIFY I/II trials [19]: (1)
clinical cure: subject received B 14-day regimen
of SoC therapy and had no diarrhoea (B 2 loose
stools per 24 h) for 2 consecutive days following
completion of SoC therapy for the baseline CDI
episode; and (2) clinical failure: subject
required[ 14-day regimen of SoC therapy for
the baseline CDI episode.
Patients experiencing relief from CDI symp-
toms (clinical cure health state) can experience
a mild/moderate or severe recurrence of CDI.
Sustained response is achieved by those who
remain in the clinical cure health state perma-
nently without experiencing subsequent recur-
rence or death.
A patient experiencing clinical failure is
treated further and eventually cured (post-clin-
ical failure health state). In the current analysis,
it was assumed that patients in post-clinical
failure health state would not experience any
recurrence of CDI since these patients were not
followed in MODIFY I/II trials, and the efficacy
of bezlotoxumab in addition to SoC was only
assessed in those who had a clinical cure.
Therefore, it was assumed that the conse-
quences of these patients would not differ
between treatment arms.
Patients who have experienced a colectomy
move to a post-colectomy health state and are
unable to experience a recurrence since CDI
symptoms are characterized by colitis.
Death may occur in any health state.
The natural history of CDI is repeated for
each recurrence, with a maximum of three
possible recurrences.
Cycle Length, Time Horizon and Discount
Rates
Given the acute nature of CDI illnesses and that
the majority of recurrences occur within
30 days of initial infection, most of the costs are
incurred within the first 6 months (180 days)
following infection. Therefore, the cycle length
was 15 days for the first 180 days, and annual
thereafter.
The model assumed a lifetime horizon in
order to ascertain the costs and benefits over the
patient’s lifetime.
A 3% annual discount rate was adopted for
both costs and benefits [23].
Model Inputs
Population characteristics (age at model entry,
proportion of females, proportion of patients
entering the model with severe CDI), first
recurrence rate, severity of recurrence and effi-
cacy of SoC were obtained from MODIFY I/II
trials [24] for each subgroup (Table 1). Second
and third recurrence rates, colectomy rates,
mortality, costs and utilities were obtained from
the literature (Table 2). Adverse events were not
considered as the overall rates showed in
MODIFY I/II trials were similar with bezlotox-
umab and placebo [24].
Conservative assumptions were made if no
data were available.
Recurrence
The rates of first recurrence for bezlotox-
umab ? SoC and SoC alone were taken from
MODIFY I/II trials for each subgroup (Table 1).
The duration of bezlotoxumab efficacy was
assumed to be 12 weeks, corresponding to the
follow-up period in the MODIFY I/II trials.
Subsequent recurrence rates were based on a
review of the literature on patients at high risk
of recurrent CDI [25] and expert opinion
(Table 2).
Efficacy of SoC
The clinical cure rates from the MODIFY I/II
trials were used to estimate the efficacy of SoC
for each subgroup (Table 1). The following
assumptions were made: SoC efficacy at
managing the index case was based on the data
from subjects without a previous episode; SoC
efficacy at managing the first recurrence was
based on the data from subjects with one pre-
vious episode; and SoC efficacy at managing the
subsequent recurrence was based on the data
from subjects with two or more episodes.
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Colectomy
The risk of colectomy and the mortality risk in
patients requiring colectomy were based on a
prospective cohort Spanish study [26], whose
aim was to evaluate the frequency, associated
risk factors and prognosis of first CDAD recur-
rences, and a literature review [27].
Mortality
The model assumes that the CDI-associated mor-
tality risk is higher during the first 180 days after
infection for patients who suffer a recurrence
(36.3%) compared to those experiencing a sus-
tained response (25.7%) based on Olsen et al. [28],
who estimated the 6-month mortality in patients
with recurrent CDI compared with patients with
CDI who did not develop a recurrence in a retro-
spective cohortofhospitalizedpatients. Given the
lack of evidence, it was assumed, based on Olsen
et al. [28], that there is no CDI-associated mor-
tality after 180 days; therefore, the mortality rate
returns to that specified by the Spanish life
tables [29] after that time.
Utility Values
Utility values for the different health states were
derived from the published literature (Table 2).
Wilcox et al. [30] conducted a retrospective
study on resource use and health-related quality
of life (HRQoL) associated with recurrent CDI
Table 1 Model parameters for each subgroup based on MODIFY I/II trials [24]
Parameters Age ‡ 65 years Severe
CDI
Immunocompromised ‡ 1 Episodes
of CDI in
previous
6 months
Age ‡ 65 years
and ‡ 1 episodes of
CDI in previous
6 months
Age, years (median) 76.58 70.99 60.7 66.11 77.00
Female, % 57.86 53.44 49.24 54.94 55.50
Patients entering the
model with severe
CDI, %
25.40 100.00 18.79 12.29 17.60
30 days recurrence rate
(ﬁrst) on
bezlotoxumab ? SoC,
%
15.38 10.66 14.61 25.00 19.38
30 days recurrence rate
(ﬁrst) on SoC, %
31.36 22.40 27.45 41.10 43.38
Proportion of recurrences
that are severe, %
15.63 41.67 15.52 4.72 8.33
SoC efﬁcacy for index
case, %
81.26 71.67 83.72 80.67 77.70
SoC efﬁcacy for ﬁrst
recurrence, %
76.74 62.16 71.67 80.67a 77.70a
SoC efﬁcacy for
subsequent recurrence,
%
80.77 66.67 76.47 82.14 80.34
CDI C. difﬁcile infection; SoC standard of care
a Model assumption: efﬁcacy for ﬁrst recurrence = efﬁcacy for index case
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hospitalizations in the UK. For the purpose of
the model, the same utility value was assumed
for health states ‘‘CDI mild/moderate’’, ‘‘CDI
severe’’, ‘‘colectomy’’ and ‘‘clinical failure’’ based
on Wilcox et al. [30]. The utility value for ‘‘post-
colectomy’’ was obtained from a publication by
Brown et al. [31], who investigated long-term
HRQoL among patients who had undergone a
colectomy within the previous 10 years. The
baseline utility values from the general popu-
lation were assumed to be applicable for ‘‘clini-
cal cure’’ and ‘‘post-clinical failure’’ health states
[32].
Costs
The cost inputs considered in the cost-effec-
tiveness analysis were bezlotoxumab drug
acquisition [20] and CDI episode (first, second
and third recurrence) costs.
Consistent to MODIFY I/II trials [19], par-
ticipants in both arms were receiving the same
SoC (metronidazole, vancomycin and/or fidax-
omicin) for 10–14 days; therefore the cost of
SoC was not included as it would have no effect
on the cost-effectiveness results.
The cost per episode of CDI was estimated
based on Asensio et al. [17], who estimated the
Table 2 Model parameters for all subgroups based on literature review
Parameter All subgroups References
Bezlotoxumab (Zinplava) acquisition cost, € €2950 [20]
Fidaxomicin (Diﬁclir) acquisition cost, € €1500 [20]
Recurrence rate (second), % 45.0 [25]
Recurrence rate (third), % 45.0 Expert opinion
Colectomy, % 1.8 [36]
Death after colectomy, % 40.0 [36]
All-cause mortality (180-days after CDI), % 25.7 (patients without subsequent
recurrences)
36.3 (patients with C 1 subsequent
recurrences)
[28]
Utility value—CDI mild/moderate 0.42 [30]
Utility value—CDI severe 0.42 [30]
Utility value—colectomy 0.42 [30]
Utility value—clinical failure 0.42 [30]
Utility value—post-colectomy 0.79 [31]
Utility value—clinical cure, post-clinical failure Baseline utility value
Males: decreasing from 0.971 (18–24 years
old) to 0.846 (75 years old or above)
Females: decreasing from 0.965
(18–24 years old) to 0.725 (75 years old
or above)
[32]
Cost of ﬁrst recurrence, € (2017) €5006.6 [17]
Cost of second and third recurrence, € (2017) €6075.7 [17]
CDI C. difﬁcile infection
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costs of CDI in Spain from the NHS perspective
including antimicrobials (metronidazole, van-
comycin), hospitalization, surgical procedures,
measures to control the infection and recur-
rences of treated infections. It should be noted
that the costs were estimated before the intro-
duction of fidaxomicin, which is expensive
compared to other SoC and often used for later
recurrences. Therefore, the costs of managing
recurrence may be underestimated leading to an
underestimation of the cost savings associated
with bezlotoxumab. This assumption was
specifically addressed in a sensitivity analysis.
Costs were inflated to 2017 euros (€), where
appropriate, using the Spanish consumer price
index [33].
ANALYSIS
Model Outputs
Model outcomes included the number of
recurrences (first, second, third and total), the
number needed to treat (NNT) to prevent one
recurrence, 180-day mortality, life-years, qual-
ity-adjusted life years (QALYs) and costs for
each treatment.
The cost-effectiveness analysis outcomes
were expressed as the cost per recurrence avoi-
ded and cost per QALY gained. The incremental
cost-effectiveness ratio (ICER) was estimated for
bezlotoxumab added to SoC compared to SoC
alone.
Sensitivity Analysis
Deterministic (DSA) and probabilistic sensitivity
analysis (PSA) were performed in order to assess
the impact of uncertainty on the ICER.
In DSA, the upper and lower bounds of the
95% confidence intervals were tested for each
parameter (see Tables S1–S5 in the electronic
supplementary material for details). When the
confidence interval was not available or could
not be estimated based on the literature, it was
estimated assuming that the standard error was
5% of the base case value. Additionally, scenario
analyses were performed in order to explore the
variation of all utility’s values at the same time
(extreme values) and the addition of the drug
acquisition cost of fidaxomicin (Table 2) to CDI
episode costs. Results of DSA were expressed as
tornado charts.
PSA was performed with 1000 Monte Carlo
simulations. The probabilities and utility values
followed a beta distribution, costs followed a
gamma distribution and for utility multipliers
that have a base case value of 1, a triangular
distribution with a mode of 1 was assumed (see
Tables S6–S10 in the electronic supplementary
material for details). Parameterization was based
on the published literature where available.
When no information on uncertainty could be
sourced, the standard error was assumed to be
5% of the base case value. ICER scatter plots and
cost-effectiveness acceptability curves were
constructed for each subgroup.
The probability of bezlotoxumab being cost-
effective at the €21, 000 per QALY gained will-
ingness-to-pay (WTP) threshold recently estab-
lished in Spain was estimated. Additionally,
alternative thresholds at €30,000/QALY and
€11,000/QALY were estimated as recommended
specifically for sensitivity analysis [34].
Compliance with Ethics Guidelines
This article does not contain any studies with
human participants or animals performed by
any of the authors.
RESULTS
Base Case Scenario
Table 3 shows a summary of the results of the
analysis. The addition of bezlotoxumab to SoC
for the prevention of recurrence in patients at
high risk of CDI recurrence compared to SoC
alone was associated with a reduction in total
recurrences and 180-day mortality and an
increase in QALYs. The ICER was therefore
€12,723.68, €17,494.70, €9544.72, €7386.38 and
€4378.20 per QALY gained, for patients aged
65 years or older, clinically severe CDI,
immunocompromised, with C 1 CDI episode in
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the previous 6 months, and aged C 65 years or
older and C 1 CDI episode in the pre vious
6 months, respectively.
Sensitivity Analysis
Deterministic Sensitivity Analysis
In the DSA, the model parameters that resulted
in the highest degree of variability in the ICER
were recurrence rate (first), all-cause mortality
(180-days after CDI), and utility value for clin-
ical cure health state (Fig. 2). In the subgroups
of patients with C 1 CDI episode in the previ-
ous 6 months and in patients aged C 65 years
and with C 1 CDI episode in the previous
6 months, all analyses were below the €21,000
per QALY gained threshold.
Probabilistic Sensitivity Analysis
PSA results showed that bezlotoxumab was cost-
effective at the €21,000 per QALY gained
threshold for most of the simulations per-
formed (Table 4). ICER scatter plots and cost-
effectiveness acceptability curves for each
subpopulation are presented in Figs. 3 and 4,
respectively.
DISCUSSION
Bezlotoxumab is the first and only drug indi-
cated to prevent recurrences of CDI in high-risk
patients. Therefore, its approach is different
from antibiotics, which are licensed only to
treat the infection. The model developed in the
present study has shown that the addition of
bezlotoxumab to SoC for the prevention of
recurrence in five populations of patients at
high risk of CDI recurrence was associated with
an ICER below the €21,000 per QALY gained
threshold [34] relative to SoC alone over a life-
time horizon from the perspective of the Span-
ish NHS. As expected, the lowest ICER
(€4378.20 per QALY gained) was estimated for
the subpopulation of patients aged 65 years or
older with a history of CDI episodes, who
achieved more health benefits, in terms of pre-
vented recurrences and 180-day mortality, with
a lower incremental cost of bezlotoxumab
Table 3 Cost-effectiveness results for the prevention of CDI with bezlotoxumab ? SoC vs. SoC in ﬁve patient population
with CDI at increased recurrence risk
Results
(bezlotoxumab 1 SoC
vs. SoC)
Age ‡ 65 years Severe
CDI
Immunocompromised ‡ 1 Episodes
of CDI in
previous
6 months
Age ‡ 65 years
and ‡ 1 episodes of
CDI in previous
6 months
Incremental total
recurrences, %
- 26.4 - 19.5 - 21.2 - 26.6 - 39.7
Incremental 180-day
mortality, %
- 1.7 - 1.1 - 1.3 - 1.7 - 2.5
NNT 3.8 5.1 4.7 3.8 2.5
Incremental cost, € 1515.5 1889.67 1797.33 1504.85 794.57
LY gained 0.15 0.13 0.22 0.24 0.22
Incremental QALYs 0.12 0.11 0.19 0.20 0.18
Cost per recurrence
avoided, €
5735.97 9681.42 8465.27 5653.53 2001.46
ICER, €/QALY gained 12,723.68 17,494.70 9544.72 7386.38 4378.20
CDI C. difﬁcile infection, ICER incremental cost-effectiveness ratio, LY life year, QALY quality-adjusted life year, SoC
standard of care
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added to SoC compared to SoC alone. We also
found that the probability of bezlotoxumab
being cost-effective with a WTP of €21,000 per
QALY gained [34] was high in all subgroups.
As mentioned before, a previous study eval-
uated the cost-effectiveness of bezlotoxumab
added to SoC compared to SoC alone in six
subgroups of patients at risk of CDI recurrence
by using the same economic model [22]. Con-
sistent with the US analysis, the present study
showed similar ICER for the subgroups that
were common between studies: C 65 years of
Fig. 2 Tornado charts of bezlotoxumab added to SoC compared to SoC alone
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age ($15,298 vs. €12,723.68 per QALY gained),
immunocompromised ($12,597 vs. €9544.72
per QALY gained), patients with a clinically
severe CDI episode ($21,430 vs. €17,494.70 per
QALY gained), and patients C 65 years of age
with C 1 episodes of CDI within the previous
6 months ($3591 vs. €4378.20 per QALY
gained). It should be noted that, according to
DSA, the main parameters influencing cost-ef-
fectiveness results were recurrence rate (first)
[19], 180-days mortality [28], and utility value
for clinical cure health state [32], and our
analysis used similar data to the US model for
these parameters.
As with any model, there are some limita-
tions in the present analysis, mainly related to
input availability and model assumptions. First,
in the absence of published studies measuring
utility among patients with CDI, natural pro-
gression of disease or updated costs from the
Spanish setting, some sources of the input
parameters used were based on different popu-
lations and some assumptions reported in
methods needed addressing. It should be noted
that, although a higher recurrence rate after the
second recurrence has been reported [25], the
clinical experts assumed 45% should be applied
to all subsequent recurrences as a conservative
assumption. Further studies are required to
obtain all these data. Second, regarding model
structure, it was assumed that patients in post-
clinical failure health state would not
experience any recurrence of CDI since these
patients were not tracked in MODIFY I/II trials.
Although this might be seen as a conservative
approach, as patients experiencing clinical fail-
ure would be treated and eventually cured,
considering recurrences after clinical failure
would lead to even higher benefits for those
patients. Third, as most clinical input parame-
ters of the model were based on MODIFY I/II
trials, in which the evaluation of CDI severity
was based on the Zar score, the proportion of
patients with a severe CDI is probably underes-
timated, since more than 90% of participants
were receiving SoC when scoring was performed
[19]. Fourth, the cost of recurrence was based on
a Spanish study which did not include fidax-
omicin as it was conducted prior to its intro-
duction. Fidaxomicin is expensive compared to
vancomycin and metronidazole, and therefore
the cost savings associated with bezlotoxumab
may be underestimated. This point was addres-
sed and confirmed in the DSA, which showed a
lower cost associated with bezlotoxumab in the
scenario analysis (addition of the drug acquisi-
tion cost of fidaxomicin to CDI episode costs)
compared with the base case. ICER was 10.34,
6.17, 7.00, 10.49 and 29.63% lower for patients
aged 65 years or older, clinically severe CDI,
immunocompromised, with C 1 CDI episode in
the previous 6 months, and aged C 65 years or
older and C 1 CDI episode in the previous
6 months, respectively, compared with the base
Table 4 Probability of bezlotoxumab ? SoC being cost-effective vs. SoC (%) at different willingness-to-pay thresholds
Threshold ‡ 65 years
old
Severe
CDI
Immunocompromised ‡ 1 CDI episodes in
previous 6 months
‡ 65 years old and with ‡ 1
CDI episodes in previous
6 months
€11,000/
QALY
gained
34.47 23.08 55.74 72.13 97.10
€21,000/
QALY
gained
85.51 54.14 86.01 94.51 99.60
€30,000/
QALY
gained
95.80 74.53 93.71 98.10 100.00
CDI C. difﬁcile infection, QALY quality adjusted life years
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case. On the other hand, it should also be noted
that, in the MODIFY I/II trials, the population
treated with fidaxomicin was small compared
with that treated with vancomycin and
metronidazole. Thus, if the population treated
with fidaxomicin were larger, it could be
expected that its greater efficacy (clinical cure)
would have an effect on the results of cost-ef-
fectiveness. However, as stated in the model,
the efficacy (clinical cure) of SoC is the same for
both treatment and comparison arms and
therefore an increase in the efficacy of SoC
should not to have a significant effect on ICER.
This fact has been equally addressed and con-
firmed by the DSA, showing minimal changes
in ICER by varying the effectiveness of SoC in
each subgroup. Fifth, the current analysis is
unable to capture the transmission of the
Fig. 3 Cost-effectiveness scatter plots of bezlotoxumab added to SoC compared to SoC alone
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disease CDI. Patients who experience recurrent
CDI have a high probability of repeating courses
of antibiotic treatment, of adverse events as well
as re-hospitalization, and acting as a reservoir of
infection that can lead to secondary infection in
other vulnerable patients [1]. Consequently, the
ability of bezlotoxumab to prevent CDI recur-
rences should also have an impact on the
overall incidence of CDI. Lastly, the cost-effec-
tiveness analysis was carried out from the per-
spective of the Spanish NHS, which may
underestimate the societal impact of the use of
bezlotoxumab, such as time lost due to CDI or
the cost of formal or informal caregivers.
Despite these limitations, a conservative
approach has been adopted for this model,
Fig. 4 Cost-effectiveness acceptability curves of bezlotoxumab added to SoC compared to SoC alone
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suggesting that the effectiveness of bezlotox-
umab could be underestimated. Future investi-
gations should address capturing the
transmission of the disease, estimating the
impact of the prevention of recurrence on the
overall incidence of CDI and taking indirect
costs and out-of-pocket costs incurred by the
patient into account.
Although the findings reported in this study
may be relevant to the Spanish healthcare sys-
tem alone, approaches that can reduce CDI-as-
sociated resource use and costs should be of
general interest [35], and the model can be
adapted to other European countries.
CONCLUSIONS
In conclusion, the results suggest that bezlotox-
umab added to SoC compared to SoC alone is a
cost-effective treatment to prevent the recur-
rence of CDI in high-risk patients from the per-
spective of the Spanish NHS being the ICER
below 21,000 per QALY gained in all subgroups.
Deterministic sensitivity analysis showed results
to be sensitive to variation in some parameters,
specifically the recurrence rate (first) and all-
causes mortality had a higher impact on the ICER
in patients aged C 65 years old, patients with
severe CDI and patients with compromised
immunity by establishing it above the threshold.
Probabilistic sensitivity analysis determined that
the probability that bezlotoxumab was cost-ef-
fective at a willingness-to-pay threshold of
€21,000/QALY was 85.5, 54.1, 86.0, 94.5 and
99.6%, for patients aged 65 years or older, clini-
cally severe CDI, immunocompromised, with
C 1 CDI episode in the previous 6 months, and
aged C 65 years or older and C 1 CDI episode in
the previous 6 months, respectively.
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